Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
T
321550
vs
K
KOSPI 200
Over the past 12 months, TiumBio Co Ltd has underperformed KOSPI 200, delivering a return of -17% compared to KOSPI 200's +116% growth.
Stocks Performance
321550 vs KOSPI 200
Performance Gap
321550 vs KOSPI 200
Performance By Year
321550 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
TiumBio Co Ltd
Glance View
TiumBio is a South Korean biotech company that develops medicines for rare and hard-to-treat diseases, with a strong focus on blood disorders such as hemophilia. It does not run a broad consumer business; instead, it works in drug research, preclinical and clinical development, and the preparation of new treatments for later approval and sale. The company’s main customers are not patients directly at this stage, but hospitals, doctors, and pharmaceutical partners that may license or help commercialize its drug candidates. TiumBio makes money through research collaboration, licensing deals, and, if its drugs are approved, future product sales or royalty streams tied to those medicines. What makes TiumBio’s business model different is that it sits at the high-risk, high-reward end of the drug value chain. Its value comes from building specialized therapies that larger drug companies may want to partner on, especially in rare diseases where there are few treatment options and small patient groups.